Sevabertinib CAS# 2521285-05-0

Sevabertinib (BAY 2927088) is a reversible, non-covalent EGFR/HER2 tyrosine kinase inhibitor that exhibits ~40-fold selectivity for EGFR exon 20 insertion mutants over wild-type EGFR and >1,000-fold selectivity for classical EGFR mutants (ex19del, L858R), maintains potency against C797S resistance mutations, and shows robust in vivo efficacy in both cell-line and patient-derived xenograft models; it also potently inhibits HER2 exon 20 insertions and point mutations with strong antiproliferative and in vivo activity.